NORML: Congress Unlikely to Block Hemp THC Ban Before Year-End

NORML Assessment Dims Legislative-Relief Prospects

NORML, the nation's oldest marijuana-reform advocacy organization, said congressional action to prevent DEA's hemp THC ban is improbable this year. The assessment follows DEA's March 2026 notice of proposed rulemaking that would reclassify products containing delta-8 THC, delta-10 THC, THC-O, and THCA as Schedule I controlled substances when derived from hemp. The divided 119th Congress lacks the votes and floor time to advance standalone hemp-protection bills before the December recess, according to NORML's legislative-affairs team.

Three obstacles block the path. Senate Judiciary Committee opposition tops the list, followed by lack of bipartisan consensus on intoxicating-hemp policy and competing farm-bill negotiations that have absorbed available legislative bandwidth. NORML Deputy Director Paul Armentano said the group now expects the DEA rule to advance to final status without congressional intervention.

DEA Rule Targets Hemp-Derived Intoxicants

The DEA's proposed rule closes the so-called "hemp loophole" created by the 2018 Farm Bill, which legalized hemp containing ≤0.3% delta-9 THC by dry weight. The notice of proposed rulemaking reinterprets 21 U.S.C. § 802(16) to classify all tetrahydrocannabinols as controlled substances when present in products intended for human consumption, regardless of source plant. On a strict reading, the rule treats delta-8 THC extracted from hemp-derived CBD as legally indistinct from delta-9 THC extracted from marijuana.

Over 43,000 public submissions flooded in before the comment period closed April 28, 2026. Industry trade groups, including the U.S. Hemp Roundtable and Hemp Industries Association, filed technical objections arguing that DEA exceeded its statutory authority under the Controlled Substances Act. DEA hasn't announced a timeline for the final rule, though agency practice suggests publication by Q4 2026.

Congressional Vehicles Stalled in Committee

Two bills introduced to preserve hemp-derived cannabinoid commerce—H.R. 1821 and S. 974—remain in committee with no floor action scheduled. H.R. 1821, the Hemp and Hemp-Derived Cannabinoid Consumer Protection Act, would amend 21 U.S.C. § 802 to explicitly exclude hemp-derived cannabinoids from Schedule I when derived from compliant hemp. The bill has 38 co-sponsors, all from hemp-producing states. It hasn't received a markup in the House Energy and Commerce Committee.

S. 974 faces steeper odds. Senate Judiciary Chair Dick Durbin (D-IL) opposes carve-outs for intoxicating hemp products, according to statements to trade press in April 2026. Without committee approval, the bill can't reach the floor under regular order. NORML's analysis concludes that neither chamber will attach hemp language to must-pass legislation such as continuing resolutions or the National Defense Authorization Act.

The hemp-delta sector, worth an estimated $2.8 billion in 2025 retail sales, now faces a binary outcome: final DEA rule or judicial relief.

Industry Prepares Legal Challenge

Trade associations are drafting a coordinated legal challenge under the Administrative Procedure Act, targeting DEA's interpretation of "hemp" and "marihuana" under 21 U.S.C. § 802. The anticipated complaint will argue that DEA's rule is arbitrary and capricious under 5 U.S.C. § 706(2)(A) because it contradicts the plain text of the 2018 Farm Bill, which removed hemp from Schedule I. Legal counsel for the U.S. Hemp Roundtable said the lawsuit will be filed in the U.S. Court of Appeals for the D.C. Circuit within 60 days of the final rule's publication in the Federal Register.

The industry's legal theory: Congress affirmatively legalized hemp and all derivatives in 7 U.S.C. § 1639o, and DEA can't re-schedule those substances without new statutory authority. Precedent from Hemp Industries Ass'n v. DEA, 333 F.3d 1082 (9th Cir. 2003), supports the argument that DEA can't expand CSA schedules to cover substances Congress has exempted.

State-Level Patchwork Likely Outcome

Absent federal clarity, states are enacting conflicting intoxicating-hemp statutes, creating a compliance patchwork. As of May 2026, 14 states have banned delta-8 THC and related analogs. Nine states have established THC-per-package limits (typically 5-10 mg per serving) and age-gated retail frameworks. Minnesota, Vermont, and California have implemented lab-testing and labeling mandates for hemp-derived cannabinoids that mirror adult-use cannabis rules.

This divergence raises interstate-commerce questions under the dormant Commerce Clause. Retailers operating in multiple states face conflicting product formulations and labeling requirements. For full background on the regulatory landscape, see the CannIntel topic hub on the federal hemp THC ban.

We'll be watching for DEA's final rule publication in Q4 2026 and the industry's D.C. Circuit filing within 60 days of that date.